SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-20-291809
Filing Date
2020-11-12
Accepted
2020-11-12 17:11:00
Documents
3
Group Members
SUMITOMO DAINIPPON PHARMA CO., LTDSUMITOVANT BIOPHARMA LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d59427dsc13da.htm SC 13D/A 72737
2 EX-6 d59427dex996.htm EX-99.6 553038
3 EX-7 d59427dex997.htm EX-99.7 59094
  Complete submission text file 0001193125-20-291809.txt   686488
Mailing Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617
Business Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617 949-226-6029
Urovant Sciences Ltd. (Subject) CIK: 0001740547 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: SC 13D/A | Act: 34 | File No.: 005-90671 | Film No.: 201307941
SIC: 2834 Pharmaceutical Preparations

Mailing Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Business Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 813-5543-5142
Sumitomo Chemical Co., Ltd. (Filed by) CIK: 0001798550 (see all company filings)

IRS No.: 980339148 | State of Incorp.: M0 | Fiscal Year End: 0331
Type: SC 13D/A